Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option

Lung Cancer. 2008 May;60(2):294-7. doi: 10.1016/j.lungcan.2007.08.031. Epub 2007 Oct 4.

Abstract

The role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. We present four cases of patients who had durable responses from pemetrexed-based chemotherapy who were retreated with a similar regimen upon progression of their mesothelioma. This case series explores the possible role of retreatment with pemetrexed-based chemotherapy as a second line therapeutic option in MPM.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Female
  • Glutamates / therapeutic use*
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Humans
  • Male
  • Mesothelioma / drug therapy*
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Pemetrexed
  • Pleural Neoplasms / drug therapy*

Substances

  • Glutamates
  • Pemetrexed
  • Guanine
  • Carboplatin